Take­da pays $5M up­front to li­cense an­ti­bod­ies for celi­ac dis­ease drug de­vel­op­ment

Take­da is work­ing on adding an­oth­er celi­ac dis­ease can­di­date to its pipeline, ink­ing a li­cens­ing deal with In­nate Phar­ma, al­low­ing it to use a pan­el of an­ti­bod­ies to re­search and de­vel­op an­ti­body-drug con­ju­gates (AD­Cs).

In ex­change for ex­clu­sive world­wide rights to what­ev­er AD­Cs are de­vel­oped us­ing a se­lec­tion of In­nate’s an­ti­bod­ies, Take­da will give In­nate a $5 mil­lion up­front pay­ment with the po­ten­tial for $410 mil­lion in mile­stones, plus roy­al­ties on net sales of any prod­uct re­sult­ing from the li­cense.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA